Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade

Trial Profile

NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; NTBI 1301; NY ESO-1 loaded dendritic cell vaccine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Feb 2019 Status changed from recruiting to discontinued.
    • 20 Dec 2018 Results safety, feasibility, and antitumor efficacy of transgenic ACT with DC vaccination, with and without CTLA-4 blockade with ipilimumab from NCT02070406 and NCT01697527, published in the Clinical Cancer Research.
    • 12 Sep 2017 Planned End Date changed from 1 Feb 2019 to 17 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top